US-based drug maker AbbVie Inc, US-based medication creator AbbVie Inc has sued the company for alleged infringement of thyroid treatment patent. Zemplar is a medication used for the prevention and treatment of supplementary hyperparathyroidism (excessive production of parathyroid hormone) correlated with chronic renal failure.
Based on reports, AbbVie Inc requested the court to deliver an order to resist DRL from commercially making, using, offering for sale, selling, marketing, importing, or distributing DRL’s generic paricalcitol injectable products prior to the expiration of said patents. Dr Reddy’s filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (USFDA), planning approval to sell a simple copy of US drug maker’s Zemplar injectable products in 2 microgram/ml and 5 microgram/ml formulations, just before the expiration of the patents owned by and exclusively authorised to the complainants, the petition allegedly mentioned.
Based on reports, AbbVie Inc requested the court to deliver an order to resist DRL from commercially making, using, offering for sale, selling, marketing, importing, or distributing DRL’s generic paricalcitol injectable products prior to the expiration of said patents. Dr Reddy’s filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (USFDA), planning approval to sell a simple copy of US drug maker’s Zemplar injectable products in 2 microgram/ml and 5 microgram/ml formulations, just before the expiration of the patents owned by and exclusively authorised to the complainants, the petition allegedly mentioned.